SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BridgeBio Pharma, Inc. Merger

Rigrodsky & Long, P.A.
·1-min read

WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches of fiduciary duties and other violations of law related to BridgeBio’s agreement to merge with Eidos Therapeutics, Inc. (“Eidos”). Under the terms of the agreement, BridgeBio will issue either $73.26 in cash or 1.85 shares of BridgeBio common stock to shareholders of Eidos.

To learn more about this investigation and your rights, visit:

You may contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.


Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530